GlassScriptPhysician profile
Charles Simmons
NPI 1255451183
$61,638.05
in general payments reported to CMS, 2019-2025
52 companies · $9,650 in 2025
The $9,650 reported for 2025 was more than what 94% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,489 · 2020: $3,560 · 2021: $6,674 · 2022: $5,082 · 2023: $16K · 2024: $11K · 2025: $9,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,955 · Honoraria: $2,000 · Travel and Lodging: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,380.33 |
| Consulting Fee | $13,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,955.00 |
| Honoraria | $2,000.00 |
| Travel and Lodging | $748.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12,279.58 | 2019-2025 | Proclaim, Eterna, Octrode |
| Vertos Medical, INC. | $12,046.43 | 2021-2024 | Mild Device Kit |
| Medtronic, INC. | $8,820.68 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Nevro Corp. | $5,308.34 | 2019-2024 | Senza |
| Boston Scientific Corporation | $4,512.21 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Stryker Corporation | $3,714.49 | 2024-2025 | Mild Device Kit, Omnicurve, Optablate |
| Elliquence, LLC | $2,000.00 | 2025 | |
| Mml US, INC. | $1,725.81 | 2021-2025 | Reactiv8 |
| Abbvie INC. | $1,533.23 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Spinal Simplicity, LLC | $1,363.35 | 2022 | |
| Horizon Therapeutics Plc | $1,237.32 | 2019-2022 | |
| Relievant Medsystems, INC. | $1,229.47 | 2022-2023 | Intracept |
| Flowonix Medical Incorporated | $840.31 | 2019-2020 | |
| Medtronic USA, INC. | $663.54 | 2019-2020 | |
| Saluda Medical Americas, INC. | $593.84 | 2024-2025 | Evoke |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.